

AMENDMENT


Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1(previously presented): A compound having the formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring;

HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinolinyl, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-;

A is -C₁-4alkyl-;

B is aryl(CH₂)₀₋₃—O—C(O)—, heteroaryl(CH₂)₁₋₃—O—C(O)—, indanyl(CH₂)₀₋₃—O—C(O)—, aryl(CH₂)₁₋₃—C(O)—, aryl—cyclopropyl—C(O)—, heteroaryl—cyclopropyl—C(O)—, heteroaryl(CH₂)₁₋₃—C(O)—, aryl(CH₂)₁₋₃—NH—C(O)—, aryl(CH₂)₁₋₃—NH—C(NCN)—, aryl(CH₂)₁₋₃—SO₂—, heteroaryl(CH₂)₁₋₃—SO₂—, wherein any of the aryl or heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro; and

X is H, OH, F, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, or X taken with an adjacent bond is =O.

Claim 2(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and~~
B is aryl(CH₂)₀₋₃—O—C(O)—, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 3(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom;
HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, —N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂—, (C₁₋₂alkyl)HNCH₂—, Si(CH₃)₃—C—, or NH₂C(O)—.

Claim 4(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is an isoxazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, —N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂—, (C₁₋₂alkyl)HNCH₂—, Si(CH₃)₃—C—, or NH₂C(O)—.

Claim 5(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a thiadiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 6(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 5 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 7(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 8(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-,

heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 9(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 10(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 11(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 12(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrrolopyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy,

hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 13(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 14(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 15(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and~~
B is aryl(CH₂)₁₋₃-SO₂-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 16(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄

4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 17(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinazolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 18(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 19(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 20(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 21(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₀₋₃-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 22(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 23(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 24(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 25(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 26(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is aryl(CH₂)₀₋₃-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 27(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 28(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 29(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 30(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is aryl(CH₂)_{1,3}-SO₂-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 31(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and~~

B is heteroaryl(CH₂)_{1,3}-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 32(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and~~

B is aryl(CH₂)₁₋₃—C(O)—, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 33(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and~~

B is aryl-cyclopropyl-C(O)—, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 34(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃—C-, or NH₂C(O)—.

Claim 35(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃—C-, or NH₂C(O)—.

Claim 36(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-,

phenylethynyl-, heteroarylethynyl-, $-N(C_0\text{-}4\text{alkyl})(C_0\text{-}4\text{alkyl})$, nitro, $(C_1\text{-}2\text{alkyl})(C_1\text{-}2\text{alkyl})NCH_2$ -, $(C_1\text{-}2\text{alkyl})HNCH_2$ -, $Si(CH_3)_3\text{-}C$ -, or $NH_2C(O)\text{-}$.

Claim 37(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is $C_1\text{-}4\text{alkyl}$, $C_1\text{-}4\text{alkoxy}$, $C_2\text{-}4\text{alkynyl}$, trifluoromethyl, hydroxy, hydroxy $C_1\text{-}4\text{alkyl}$, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, $-N(C_0\text{-}4\text{alkyl})(C_0\text{-}4\text{alkyl})$, nitro, $(C_1\text{-}2\text{alkyl})(C_1\text{-}2\text{alkyl})NCH_2$ -, $(C_1\text{-}2\text{alkyl})HNCH_2$ -, $Si(CH_3)_3\text{-}C$ -, or $NH_2C(O)\text{-}$.


Claim 38(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein


~~NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and~~
B is heteroaryl $(CH_2)_{1\text{-}3}\text{-}O\text{-}C(O)\text{-}$, wherein the heteroaryl is optionally substituted by 1-5 substituents, each substituent independently is $C_1\text{-}4\text{alkyl}$, $C_3\text{-}6\text{cycloalkyl}$, $C_1\text{-}4\text{alkoxy}$, trifluoromethyl, bromo, fluoro, or chloro;.


Claim 39(currently amended): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein


~~NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and~~
B is aryl $(CH_2)_{1\text{-}3}\text{-}NH\text{-}C(NCN)\text{-}$, wherein the aryl is optionally substituted by 1-5 substituents, each substituent independently is $C_1\text{-}4\text{alkyl}$, $C_3\text{-}6\text{cycloalkyl}$, $C_1\text{-}4\text{alkoxy}$, trifluoromethyl, bromo, fluoro, or chloro.


Claim 40(original): The compound according to Claim 1, wherein said compound is



















or a pharmaceutically acceptable salt thereof.


Claim 41(original): The compound according to Claim 1, wherein said compound is






or a pharmaceutically acceptable salt thereof.


Claim 42(withdrawn): The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.


Claim 43(previously presented): A compound represented by







or a pharmaceutically acceptable salt thereof.

Claim 44(previously presented): The compound according to Claim 1, wherein said compound is











or a pharmaceutically acceptable salt thereof.

Claim 45 (previously presented): The compound according to Claim 1, wherein said compound is











or a pharmaceutically acceptable salt thereof.

Claim 46 (previously presented): The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.

Claim 47(withdrawn): The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.

Claim 48(original): A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

Claim 49(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat pain.

Claim 50(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.

Claim 51(original): A method of treating pain comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

Serial No.: 10/079,452
Case No.: 20832Y
Page No.: 27

Claim 52(original): A method of treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.